Sarepta names former Regeneron exec as CMO

US biotech firm Sarepta Therapeutics (Nasdaq SRPT) today announced the appointment of Catherine Stehman-Breen, as chief medical officer.

Dr Stehman-Breen joins Sarepta after having served as vice president, clinical development and regulatory affairs at Regeneron Pharmaceuticals (Nasdaq: REGN) since 2015, initially as head, pain therapeutic area, and subsequently as head, clinical project management and operations. From 2003 to 2015, she held senior leadership roles at Amgen including vice president, global development, leading the neuroscience, nephrology and bone therapeutic areas.

“I deeply admire Sarepta’s profound commitment to improving the lives of boys with Duchenne muscular dystrophy and the exciting and innovative PMO and PPMO platform that is being harnessed to achieve this goal,” said Dr Stehman-Breen. “I am excited to join the company at a time when it is rapidly building and look forward to working closely with the internal team and external collaborators as we seek to develop and commercialize novel therapies that address this significant unmet medical need.”